IL6 and COVID-19: These findings make a strong agreement with the previous clinical findings that intravenous injection of CIGB-258 (1–2 mg) suppressed cytokine cascade in hyperinflammatory COVID-19 patients via controlling neutrophil activation with lowering IL-6, IL-10, TNF-α, and CRP, and raising regulatory T cells (Treg) [16].